Shots:
- Nurix reported updated P-Ia/I b data for bexobrutideg in which P-Ia (n=48) showed an ORR of 83% incl. 2 CRs & a median PFS of 22.1mos. across all doses (50 mg to 600 mg OD) in heavily pretreated relapsed/refractory CLL/SLL pts.; P-Ib data (n=42) indicated higher ORR i.e. 83.3% & longer PFS at the 600mg RP2D vs the 200mg dose
- Bexobrutideg was well tolerated across dose levels, safety at the 600mg RP2D was consistent with the overall study population, and updated findings include meaningful responses across high-risk subgroups, BTKi/BCL-2 double-exposed pts., and those with BTK/PLCG2/TP53 mutations
- The P-II (DAYBreak-CLL-201) study is currently enrolling patients globally, and Nurix also continues the enrollment in the P-Ia/Ib (NX-5948-301) study
Ref: Nurix Therapeutics | Image: Nurix Therapeutics | Press Release
Related News: Sanofi Licenses an Undisclosed Nurix Therapeutics’ Drug Program for Autoimmune Diseases
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
